New horizons in the pharmacologic approach to hyponatremia: The V 2 receptor antagonists

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


This article provides an overview of the developing niche for vasopressin 2 receptor antagonists ("vaptans") in the management of hyponatremia in clinical practice. Specific areas of focus include the physiological and clinical rationale for use of this class of medications (including advantages over older and less specific therapeutic modalities), the practical limitations to the use of these new drugs (including issues of tolerability, toxicity, risk, and cost), and the unanswered question of the extent to which correcting hyponatremia will improve clinical outcomes.

Original languageEnglish (US)
Pages (from-to)S27-S32
JournalJournal of hospital medicine
Issue numberSUPPL. 3
StatePublished - Jul 1 2010


  • AVP receptor antagonists
  • Arginine vasopressin
  • Conivaptan
  • Hyponatremia
  • Tolvaptan

ASJC Scopus subject areas

  • Leadership and Management
  • Internal Medicine
  • Fundamentals and skills
  • Health Policy
  • Care Planning
  • Assessment and Diagnosis


Dive into the research topics of 'New horizons in the pharmacologic approach to hyponatremia: The V <sub>2</sub> receptor antagonists'. Together they form a unique fingerprint.

Cite this